⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 28, 2024Current Medical Research and OpinionOpen Access

Evaluation of rimegepant utilization patterns and patient characteristics among new users: a United States administrative claims-based study

Jessica Ailani Motomori O. Lewis Feng Dai Aaron Jenkins Jessica Cirillo Karin Hygge Blakeman Lucy Abraham Joshua D. Brown

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

To assess tablet utilization patterns and describe pre-treatment characteristics among new users of rimegepant.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ailani et al. (2024) studied this question.

synapsesocial.com/papers/68e57180b6db6435875120da https://doi.org/10.1080/03007995.2024.2410930

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States2024 · 8 citations
2Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics2024 · 11 citations
3Post-marketing safety concerns with rimegepant based on a pharmacovigilance study2024 · 6 citations
4Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraineMeta-Analysis · 2026 · 1 citations
5Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China2025 · 3 citations

Consistency of response to rimegepant for the acute treatment of migraine among real-world users – findings from the prospective observational CONFIDENCE study2026
RIMEGEPANT AS A NOVEL THERAPEUTIC OPTION FOR MIGRAINE: A SYSTEMATIC REVIEW OF SAFETY AND TOLERABILITY2026
Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States2026
Primary immune thrombocytopenia in Italy: epidemiology, management pathways, and the clinical–economic impact of corticosteroidsCurrent Medical Research and Opinion · 2026
Over-the-counter topical diclofenac in musculoskeletal pain: clinical value, access and responsible useCurrent Medical Research and Opinion · 2026

More from Current Medical Research and Opinion

More from Georgetown University

More from Pfizer (United States)

More from Pfizer (United Kingdom)

More from MedStar Georgetown University Hospital

More from Pfizer (Sweden)